Anle138b Seen as Safe and Moving to Patient Trial With MJFF Support
The small molecule anle138b has shown “excellent” safety and tolerability profiles in a first study in healthy volunteers, and reached therapeutic dose levels in the blood, according to its developer Modag. These results enabled Modag to secure an additional $1.4 million in funding from the Michael J.